Press coverage about Epizyme (NASDAQ:EPZM) has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Epizyme earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.2945395003716 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Epizyme (NASDAQ EPZM) opened at $14.90 on Friday. The firm has a market cap of $1,034.04, a price-to-earnings ratio of -6.56 and a beta of 2.00. Epizyme has a 52-week low of $9.30 and a 52-week high of $20.45.
Epizyme (NASDAQ:EPZM) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.02. equities research analysts anticipate that Epizyme will post -2.23 earnings per share for the current year.
A number of equities research analysts recently issued reports on the stock. BidaskClub upgraded shares of Epizyme from a “sell” rating to a “hold” rating in a report on Saturday, January 6th. Zacks Investment Research upgraded shares of Epizyme from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a report on Monday, October 16th. Morgan Stanley assumed coverage on shares of Epizyme in a report on Wednesday, January 10th. They issued an “overweight” rating and a $20.00 price objective for the company. Leerink Swann reiterated an “outperform” rating and issued a $22.00 price objective (down from $28.00) on shares of Epizyme in a report on Thursday, November 2nd. Finally, Oppenheimer set a $26.00 price objective on shares of Epizyme and gave the stock a “buy” rating in a report on Tuesday, December 12th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company’s stock. Epizyme has an average rating of “Buy” and a consensus price target of $22.40.
In other Epizyme news, insider Peter Tai-Ching Ho sold 15,000 shares of the business’s stock in a transaction on Tuesday, October 24th. The shares were sold at an average price of $16.44, for a total transaction of $246,600.00. Following the completion of the transaction, the insider now owns 23,123 shares of the company’s stock, valued at approximately $380,142.12. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 25.20% of the stock is owned by insiders.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.